Tandem Diabetes (TNDM) Misses Q2 EPS by 82c, Revenues Beat; Offers FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Tandem Diabetes Care Reports Second Quarter 2018 Financial Results
July 30, 2018 4:05 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pump available in the United States, today reported its financial results for the quarter ended June 30, 2018.
Second Quarter 2018 Results
In comparing the second quarter of 2018 to the same period of 2017:
Pump shipments increased 59 percent to 5,447 pumps from 3,427 pumps Sales increased 60 percent to $34.1 million from $21.3 million Operating margin improved to negative 41 percent from negative 89 percent... More
